{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:23:33Z","timestamp":1795065813209,"version":"4.10.2"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Fungal infections have shown an upsurge in recent decades, which is mainly because of the increasing number of immunocompromised patients and the occurrence of invasive candidiasis has been found to be 7-15 fold greater than that of invasive aspergillosis. The genus Candida comprises more than 150 distinct species, however, only a few of them are found to be pathogenic to humans. Mortality rates of Candida species are found to be around 45% and the reasons for this intensified mortality are inefficient diagnostic techniques and unfitting initial treatment strategies. There are only a few antifungal drug classes that are employed for the remedy of invasive fungal infections. which include azoles, polyenes, echinocandins, and pyrimidine analogs. During the last 2-3 decades, the usage of antifungal drugs has increased several folds due to which the reports of escalating antifungal drug resistance have also been recorded. The resistance is mostly to the triazole- based compounds. Due to the occurrence of antifungal drug resistance, the success rates of treatment have been reduced as well as major changes have been observed in the frequency of fungal infections. In this review, we have summarized the major molecular mechanisms for the development of antifungal drug resistance.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450122666210719124143","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T07:26:39Z","timestamp":1626765999000},"page":"116-125","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antimycotic Drugs and their Mechanisms of Resistance to Candida Species"],"prefix":"10.2174","volume":"23","author":[{"given":"Sweety","family":"Dahiya","sequence":"first","affiliation":[{"name":"Centre for Biotechnology, Maharshi Dayanand University Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Sharma","sequence":"additional","affiliation":[{"name":"Centre for Biotechnology, Maharshi Dayanand University Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Punia","sequence":"additional","affiliation":[{"name":"Centre for Biotechnology, Maharshi Dayanand University Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Centre for Biotechnology, Maharshi Dayanand University Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prity","family":"Gulia","sequence":"additional","affiliation":[{"name":"Centre for Biotechnology, Maharshi Dayanand University Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virinder S.","family":"Parmar","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Environmental Science, Medgar Evers College, The City University of New York, 1638 Bedford Avenue, Brooklyn, NY 11225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Chhillar","sequence":"additional","affiliation":[{"name":"Centre for Biotechnology, Maharshi Dayanand University Rohtak, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nyas.13739","volume":"1435","author":"Geddes-McAlister J.","year":"2019","unstructured":"Geddes-McAlister J.; Shapiro R.S.; New pathogens, new tricks: Emerging, drug-resistant fungal pathogens and future prospects for antifungal therapeutics. Ann N Y Acad Sci 2019,1435(1),57-78","journal-title":"Ann N Y Acad Sci"},{"key":"ref=2","first-page":"923","author":"Denning D.W.","year":"2017","unstructured":"Denning D.W.; To accompany the country burden papers from 14 countries european journal of clinical microbiology 2017,923-924","journal-title":"To accompany the country burden papers from 14 countries european journal of clinical microbiology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"Pfaller M.A.","year":"2007","unstructured":"Pfaller M.A.; Diekema D.J.; Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007,20(1),133-163","journal-title":"Clin Microbiol Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"Wisplinghoff H.","year":"2004","unstructured":"Wisplinghoff H.; Bischoff T.; Tallent S.M.; Seifert H.; Wenzel R.P.; Edmond M.B.; Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004,39(3),309-317","journal-title":"Clin Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.14740\/jocmr2992w","volume":"9","author":"Campitelli M.","year":"2017","unstructured":"Campitelli M.; Zeineddine N.; Samaha G.; Maslak S.; Combination antifungal therapy: A review of current data. J Clin Med Res 2017,9(6),451-456","journal-title":"J Clin Med Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.mib.2011.06.001","volume":"14","author":"Ganguly S.","year":"2011","unstructured":"Ganguly S.; Mitchell A.P.; Mucosal biofilms of candida albicans. Curr Opin Microbiol 2011,14(4),380-385","journal-title":"Curr Opin Microbiol"},{"key":"ref=7","first-page":"1","volume":"1","author":"Article R.","year":"2018","unstructured":"Article R.; Review on combinatorial approach for inhibiting candida albicans biofilm. OPEN ACCESS 2018,1(5),1-10","journal-title":"OPEN ACCESS"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0966-842X(02)00002-1","volume":"11","author":"Douglas L.J.","year":"2003","unstructured":"Douglas L.J.; Candida biofilms and their role in infection. Trends Microbiol 2003,11(1),30-36","journal-title":"Trends Microbiol"},{"key":"ref=9","volume":"3","author":"Bongomin F","year":"2017","unstructured":"Bongomin F; Gago S; Oladele RO; Denning DW; Global and multi-national prevalence of fungal diseases-estimate precision. J fungi (Basel, Switzerland) 2017,3(4)","journal-title":"J fungi (Basel, Switzerland)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"Brown G.D.","year":"2012","unstructured":"Brown G.D.; Denning D.W.; Gow N.A.R.; Levitz S.M.; Netea M.G.; White T.C.; Hidden killers: Human fungal infections. Sci Transl Med 2012,4(165),165rv13","journal-title":"Sci Transl Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.micinf.2009.04.018","volume":"11","author":"Hasan F.","year":"2009","unstructured":"Hasan F.; Xess I.; Wang X.; Jain N.; Fries B.C.; Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect 2009,11(8-9),753-761","journal-title":"Microbes Infect"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.tim.2004.05.008","volume":"12","author":"Sudbery P.","year":"2004","unstructured":"Sudbery P.; Gow N.; Berman J.; The distinct morphogenic states of Candida albicans. Trends Microbiol 2004,12(7),317-324","journal-title":"Trends Microbiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"363764","DOI":"10.1155\/2012\/363764","volume":"2012","author":"Maccallum D.M.","year":"2012","unstructured":"Maccallum D.M.; Hosting infection: Experimental models to assay Candida virulence. Int J Microbiol 2012,2012,363764","journal-title":"Int J Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"204237","DOI":"10.1155\/2013\/204237","volume":"2013","author":"Spampinato C.","year":"2013","unstructured":"Spampinato C.; Leonardi D.; Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents. BioMed Res Int 2013,2013,204237","journal-title":"BioMed Res Int"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1473-3099(10)70218-8","volume":"11","author":"Miceli M.H.","year":"2011","unstructured":"Miceli M.H.; D&#xED;az J.A.; Lee S.A.; Emerging opportunistic yeast infections. Lancet Infect Dis 2011,11(2),142-151","journal-title":"Lancet Infect Dis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.3390\/jof4030105","volume":"4","author":"Healey K.R.","year":"2018","unstructured":"Healey K.R.; Perlin D.S.; Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata. J Fungi (Basel) 2018,4(3),E105","journal-title":"J Fungi (Basel)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","volume":"39","author":"Kett D.H.","year":"2011","unstructured":"Kett D.H.; Azoulay E.; Echeverria P.M.; Vincent J-L.; Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011,39(4),665-670","journal-title":"Crit Care Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/myc.12330","volume":"58","author":"Sanguinetti M.","year":"2015","unstructured":"Sanguinetti M.; Posteraro B.; Lass-Fl&#xF6;rl C.; Antifungal drug resistance among Candida species: Mechanisms and clinical impact. Mycoses 2015,58(S2)(Suppl. 2),2-13","journal-title":"Mycoses"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/cid\/cis697","volume":"55","author":"Cleveland A.A.","year":"2012","unstructured":"Cleveland A.A.; Farley M.M.; Harrison L.H.; Stein B.; Hollick R.; Lockhart S.R.; Magill S.S.; Derado G.; Park B.J.; Chiller T.M.; Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012,55(10),1352-1361","journal-title":"Clin Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1128\/JCM.40.4.1298-1302.2002","volume":"40","author":"Diekema D.J.","year":"2002","unstructured":"Diekema D.J.; Messer S.A.; Brueggemann A.B.; Coffman S.L.; Doern G.V.; Herwaldt L.A.; Pfaller M.A.; Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002,40(4),1298-1302","journal-title":"J Clin Microbiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/1471-2334-10-312","volume":"10","author":"Poikonen E.","year":"2010","unstructured":"Poikonen E.; Lyytik&#xE4;inen O.; Anttila V-J.; Koivula I.; Lumio J.; Kotilainen P.; Syrj&#xE4;l&#xE4; H.; Ruutu P.; Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010,10(1),312","journal-title":"BMC Infect Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1099\/jmm.0.47239-0","volume":"56","author":"Odds F.C.","year":"2007","unstructured":"Odds F.C.; Hanson M.F.; Davidson A.D.; Jacobsen M.D.; Wright P.; Whyte J.A.; Gow N.A.R.; Jones B.L.; One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007,56(Pt 8),1066-1075","journal-title":"J Med Microbiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1128\/JCM.00029-06","volume":"44","author":"Sandven P.","year":"2006","unstructured":"Sandven P.; Bevanger L.; Digranes A.; Haukland H.H.; Manns&#xE5;ker T.; Gaustad P.; Candidemia in Norway (1991 to 2003): Results from a nationwide study. J Clin Microbiol 2006,44(6),1977-1981","journal-title":"J Clin Microbiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijantimicag.2006.01.002","volume":"27","author":"Tortorano A.M.","year":"2006","unstructured":"Tortorano A.M.; Kibbler C.; Peman J.; Bernhardt H.; Klingspor L.; Grillot R.; Candidaemia in Europe: Epidemiology and resistance. Int J Antimicrob Agents 2006,27(5),359-366","journal-title":"Int J Antimicrob Agents"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1128\/JCM.43.4.1829-1835.2005","volume":"43","author":"Almirante B.","year":"2005","unstructured":"Almirante B.; Rodr&#xED;guez D.; Park B.J.; Cuenca-Estrella M.; Planes A.M.; Almela M.; Mensa J.; Sanchez F.; Ayats J.; Gimenez M.; Saballs P.; Fridkin S.K.; Morgan J.; Rodriguez-Tudela J.L.; Warnock D.W.; Pahissa A.; Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005,43(4),1829-1835","journal-title":"J Clin Microbiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3201\/eid0908.030069","volume":"9","author":"Poikonen E.","year":"2003","unstructured":"Poikonen E.; Lyytik&#xE4;inen O.; Anttila V-J.; Ruutu P.; Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003,9(8),985-990","journal-title":"Emerg Infect Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e01588-17","DOI":"10.1128\/JCM.01588-17","volume":"56","author":"Spivak E.S.","year":"2018","unstructured":"Spivak E.S.; Hanson K.E.; Candida auris: An Emerging Fungal Pathogen. J Clin Microbiol 2018,56(2),e01588-17","journal-title":"J Clin Microbiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1016\/j.ijid.2010.04.006","volume":"14","author":"Falagas M.E.","year":"2010","unstructured":"Falagas M.E.; Roussos N.; Vardakas K.Z.; Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010,14(11),e954-e966","journal-title":"Int J Infect Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1567-1364.2006.00117.x","volume":"6","author":"Ramage G.","year":"2006","unstructured":"Ramage G.; Mart&#xED;nez J.P.; L&#xF3;pez-Ribot J.L.; Candida biofilms on implanted biomaterials: A clinically significant problem. FEMS Yeast Res 2006,6(7),979-986","journal-title":"FEMS Yeast Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd.2017.46","volume":"16","author":"Perfect J.R.","year":"2017","unstructured":"Perfect J.R.; The antifungal pipeline: A reality check. Nat Rev Drug Discov 2017,16(9),603-616","journal-title":"Nat Rev Drug Discov"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1473-3099(02)00181-0","volume":"2","author":"Sanglard D.","year":"2002","unstructured":"Sanglard D.; Odds F.C.; Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002,2(2),73-85","journal-title":"Lancet Infect Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nchembio.1496","volume":"10","author":"Anderson T.M.","year":"2014","unstructured":"Anderson T.M.; Clay M.C.; Cioffi A.G.; Diaz K.A.; Hisao G.S.; Tuttle M.D.; Nieuwkoop A.J.; Comellas G.; Maryum N.; Wang S.; Uno B.E.; Wildeman E.L.; Gonen T.; Rienstra C.M.; Burke M.D.; Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 2014,10(5),400-406","journal-title":"Nat Chem Biol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/0929867033368448","volume":"10","author":"Zotchev S.B.","year":"2003","unstructured":"Zotchev S.B.; Polyene macrolide antibiotics and their applications in human therapy. Curr Med Chem 2003,10(3),211-223","journal-title":"Curr Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc6212","volume":"12","author":"M&#xE9;an M.","year":"2008","unstructured":"M&#xE9;an M.; Marchetti O.; Calandra T.; Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008,12(1),204","journal-title":"Crit Care"},{"key":"ref=35","volume":"9","author":"Wall G","year":"2020","unstructured":"Wall G; Lopez-Ribot JL; Current antimycotics, new prospects, and future approaches to antifungal therapy. Antibiot (Basel, Switzerland) 2020,9(8)","journal-title":"Antibiot (Basel, Switzerland)"},{"key":"ref=36","author":"Padda I.S.","year":"2020","unstructured":"Padda I.S.; Parmar M.; In: StatPearls 2020","journal-title":"In: StatPearls"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jac\/46.2.171","volume":"46","author":"Vermes A.","year":"2000","unstructured":"Vermes A.; Guchelaar H.J.; Dankert J.; Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000,46(2),171-179","journal-title":"J Antimicrob Chemother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1439-0507.2006.01295.x","volume":"49","author":"Hof H.","year":"2006","unstructured":"Hof H.; A new, broad-spectrum azole antifungal: Posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses 2006,49(Suppl. 1),2-6","journal-title":"Mycoses"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"Pappas P.G.","year":"2016","unstructured":"Pappas P.G.; Kauffman C.A.; Andes D.R.; Clancy C.J.; Marr K.A.; Ostrosky-Zeichner L.; Reboli A.C.; Schuster M.G.; Vazquez J.A.; Walsh T.J.; Zaoutis T.E.; Sobel J.D.; Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis [Internet].2016,62(4),e1-e50","journal-title":"Clin Infect Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","volume":"71","author":"Lass-Fl&#xF6;rl C.","year":"2011","unstructured":"Lass-Fl&#xF6;rl C.; Triazole antifungal agents in invasive fungal infections: A comparative review. Drugs 2011,71(18),2405-2419","journal-title":"Drugs"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bcp.2016.11.019","volume":"133","author":"Campoy S.","year":"2017","unstructured":"Campoy S.; Adrio J.L.; Antifungals. Biochem Pharmacol 2017,133,86-96","journal-title":"Biochem Pharmacol"},{"key":"ref=42","first-page":"897","volume":"Vol. 46","author":"Mellinghoff S.C.","year":"2018","unstructured":"Mellinghoff S.C.; Cornely O.A.; Jung N.; 2018,Vol. 46,897-899"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02586-18","volume":"63","author":"Warrilow A.G.","year":"2019","unstructured":"Warrilow A.G.; Nishimoto A.T.; Parker J.E.; Price C.L.; Flowers S.A.; Kelly D.E.; Rogers P.D.; Kelly S.L.; The evolution of azole resistance in candida albicans sterol 14-demethylase (CYP51) through incremental amino acid substitutions. Antimicrob Agents Chemother 2019,63(5),1-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1586\/14787210.2015.1032939","volume":"13","author":"Allen D.","year":"2015","unstructured":"Allen D.; Wilson D.; Drew R.; Perfect J.; Azole antifungals: 35 years of invasive fungal infection management. Expert Rev Anti Infect Ther 2015,13(6),787-798","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0253-7613.62396","volume":"42","author":"Grover N.D.","year":"2010","unstructured":"Grover N.D.; Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol 2010,42(1),9-11","journal-title":"Indian J Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","volume":"362","author":"Denning D.W.","year":"2003","unstructured":"Denning D.W.; Echinocandin antifungal drugs. Lancet 2003,362(9390),1142-1151","journal-title":"Lancet"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","volume":"73","author":"Bader JC","year":"2018","unstructured":"Bader JC; Bhavnani SM; Andes DR; Ambrose PG; We can do better: A fresh look at echinocandin dosing. J Antimicrob Chemother 2018,73(suppl 1),i44-i50","journal-title":"J Antimicrob Chemother"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1592\/phco.27.3.369","volume":"27","author":"Cappelletty D.","year":"2007","unstructured":"Cappelletty D.; Eiselstein-McKitrick K.; The echinocandins. Pharmacotherapy 2007,27(3),369-388","journal-title":"Pharmacotherapy"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.clinthera.2005.06.010","volume":"27","author":"Vazquez J.A.","year":"2005","unstructured":"Vazquez J.A.; Anidulafungin: A new echinocandin with a novel profile. Clin Ther 2005,27(6),657-673","journal-title":"Clin Ther"},{"key":"ref=50","volume":"6","author":"Zhao Y","year":"2020","unstructured":"Zhao Y; Perlin DS; Review of the novel echinocandin antifungal rezafungin: Animal studies and clinical data. J Fungi (Basel, Switzerland) 2020,6(4)","journal-title":"J Fungi (Basel, Switzerland)"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","volume":"10","author":"Perlin D.S.","year":"2007","unstructured":"Perlin D.S.; Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007,10(3),121-130","journal-title":"Drug Resist Updat"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e1004668","DOI":"10.1371\/journal.ppat.1004668","volume":"11","author":"Shor E.","year":"2015","unstructured":"Shor E.; Perlin D.S.; Coping with stress and the emergence of multidrug resistance in fungi. PLoS Pathog 2015,11(3),e1004668","journal-title":"PLoS Pathog"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","volume":"6","author":"Pfaller M.A.","year":"2019","unstructured":"Pfaller M.A.; Diekema D.J.; Turnidge J.D.; Castanheira M.; Jones R.N.; Twenty years of the sentry antifungal surveillance program: Results for Candida Species From 1997-2016. Open Forum Infect Dis 2019,6(Suppl. 1),S79-S94","journal-title":"Open Forum Infect Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.idc.2015.10.013","volume":"30","author":"McCarty T.P.","year":"2016","unstructured":"McCarty T.P.; Pappas P.G.; Invasive Candidiasis. Infect Dis Clin North Am 2016,30(1),103-124","journal-title":"Infect Dis Clin North Am"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mib.2018.02.005","volume":"45","author":"Revie N.M.","year":"2018","unstructured":"Revie N.M.; Iyer K.R.; Robbins N.; Cowen L.E.; Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol 2018,45,70-76","journal-title":"Curr Opin Microbiol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/jac\/45.2.239","volume":"45","author":"Rodero L.","year":"2000","unstructured":"Rodero L.; C&#xF3;rdoba S.; Cahn P.; Hochenfellner F.; Davel G.; Canteros C.; Kaufman S.; Guelfand L.; In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. J Antimicrob Chemother 2000,45(2),239-242","journal-title":"J Antimicrob Chemother"},{"key":"ref=57","volume":"6","author":"Carolus H","year":"2020","unstructured":"Carolus H; Pierson S; Lagrou K; Van Dijck P.; Amphotericin B and Other polyenes-discovery, clinical use, mode of action and drug resistance. J fungi Basel, Switzerland 2020,6(4)","journal-title":"J fungi Basel, Switzerland"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1130-1406(08)70027-5","volume":"25","author":"Espinel-Ingroff A.","year":"2008","unstructured":"Espinel-Ingroff A.; Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi. Rev Iberoam Micol 2008,25(2),101-106","journal-title":"Rev Iberoam Micol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1128\/AAC.01510-06","volume":"51","author":"Vandeputte P.","year":"2007","unstructured":"Vandeputte P.; Tronchin G.; Berg&#xE8;s T.; Hennequin C.; Chabasse D.; Bouchara J-P.; Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob Agents Chemother 2007,51(3),982-990","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1586\/eri.09.18","volume":"7","author":"Pem&#xE1;n J.","year":"2009","unstructured":"Pem&#xE1;n J.; Cant&#xF3;n E.; Espinel-Ingroff A.; Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther 2009,7(4),453-460","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11046-010-9342-1","volume":"171","author":"Vandeputte P.","year":"2011","unstructured":"Vandeputte P.; Pineau L.; Larcher G.; Noel T.; Br&#xE8;thes D.; Chabasse D.; Bouchara J.P.; Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata. Mycopathologia 2011,171(1),11-21","journal-title":"Mycopathologia"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1128\/AAC.49.8.3101-3108.2005","volume":"49","author":"Chapeland-Leclerc F.","year":"2005","unstructured":"Chapeland-Leclerc F.; Bouchoux J.; Goumar A.; Chastin C.; Villard J.; No&#xEB;l T.; Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob Agents Chemother 2005,49(8),3101-3108","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-200161001-00002","volume":"61","author":"Meis J.F.","year":"2001","unstructured":"Meis J.F.; Verweij P.E.; Current management of fungal infections. Drugs 2001,61(Suppl. 1),13-25","journal-title":"Drugs"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1517\/13543784.9.3.593","volume":"9","author":"Hoffman H.L.","year":"2000","unstructured":"Hoffman H.L.; Ernst E.J.; Klepser M.E.; Novel triazole antifungal agents. Expert Opin Investig Drugs 2000,9(3),593-605","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1465-0691.2004.1004.x","volume":"10","author":"Livermore D.M.","year":"2004","unstructured":"Livermore D.M.; The need for new antibiotics. Clin Microbiol Infect 2004,10(Suppl. 4),1-9","journal-title":"Clin Microbiol Infect"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1128\/JCM.41.2.619-622.2003","volume":"41","author":"Redding S.W.","year":"2003","unstructured":"Redding S.W.; Kirkpatrick W.R.; Saville S.; Coco B.J.; White W.; Fothergill A.; Rinaldi M.; Eng T.; Patterson T.F.; Lopez-Ribot J.; Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol 2003,41(2),619-622","journal-title":"J Clin Microbiol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1358\/dot.2015.51.12.2421058","volume":"51","author":"Peyton L.R.","year":"2015","unstructured":"Peyton L.R.; Gallagher S.; Hashemzadeh M.; Triazole antifungals: a review. Drugs Today (Barc) 2015,51(12),705-718","journal-title":"Drugs Today (Barc)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/EC.00041-08","volume":"7","author":"Cowen L.E.","year":"2008","unstructured":"Cowen L.E.; Steinbach W.J.; Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008,7(5),747-764","journal-title":"Eukaryot Cell"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrmicro1179","volume":"3","author":"Anderson J.B.","year":"2005","unstructured":"Anderson J.B.; Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 2005,3(7),547-556","journal-title":"Nat Rev Microbiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1128\/CMR.00051-08","volume":"22","author":"Cannon R.D.","year":"2009","unstructured":"Cannon R.D.; Lamping E.; Holmes A.R.; Niimi K.; Baret P.V.; Keniya M.V.; Tanabe K.; Niimi M.; Goffeau A.; Monk B.C.; Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 2009,22(2),291-321","journal-title":"Clin Microbiol Rev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1534\/genetics.105.054767","volume":"172","author":"Coste A.","year":"2006","unstructured":"Coste A.; Turner V.; Ischer F.; Morschh&#xE4;user J.; Forche A.; Selmecki A.; Berman J.; Bille J.; Sanglard D.; A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 2006,172(4),2139-2156","journal-title":"Genetics"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1128\/EC.3.6.1639-1652.2004","volume":"3","author":"Coste A.T.","year":"2004","unstructured":"Coste A.T.; Karababa M.; Ischer F.; Bille J.; Sanglard D.; TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004,3(6),1639-1652","journal-title":"Eukaryot Cell"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1128\/EC.00069-09","volume":"8","author":"Coste A.T.","year":"2009","unstructured":"Coste A.T.; Crittin J.; Bauser C.; Rohde B.; Sanglard D.; Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot Cell 2009,8(8),1250-1267","journal-title":"Eukaryot Cell"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2147\/IDR.S202058","volume":"12","author":"Yao D.","year":"2019","unstructured":"Yao D.; Chen J.; Chen W.; Li Z.; Hu X.; Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China. Infect Drug Resist 2019,12,771-781","journal-title":"Infect Drug Resist"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2958.2008.06143.x","volume":"68","author":"Torelli R.","year":"2008","unstructured":"Torelli R.; Posteraro B.; Ferrari S.; La Sorda M.; Fadda G.; Sanglard D.; Sanguinetti M.; The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol 2008,68(1),186-201","journal-title":"Mol Microbiol"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.48.5.1773-1777.2004","volume":"48","author":"Bennett J.E.","year":"2004","unstructured":"Bennett J.E.; Izumikawa K.; Marr K.A.; Mechanism of increased fluconazole resistance in Candida glabrata during Prophylaxis. Antimicrob agents chemother 2004,48(5),1773-1777","journal-title":"Antimicrob agents chemother"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"E332","DOI":"10.3390\/genes9070332","volume":"9","author":"Cavalheiro M.","year":"2018","unstructured":"Cavalheiro M.; Pais P.; Galocha M.; Teixeira M.C.; Host-Pathogen interactions mediated by mdr transporters in fungi: As pleiotropic as it Gets! Genes (Basel) 2018,9(7),E332","journal-title":"Genes (Basel)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1128\/AAC.01095-08","volume":"53","author":"Lamping E.","year":"2009","unstructured":"Lamping E.; Ranchod A.; Nakamura K.; Tyndall J.D.A.; Niimi K.; Holmes A.R.; Niimi M.; Cannon R.D.; Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob Agents Chemother 2009,53(2),354-369","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/mmy.39.1.109.116","volume":"39","author":"Katiyar S.K.","year":"2001","unstructured":"Katiyar S.K.; Edlind T.D.; Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med Mycol 2001,39(1),109-116","journal-title":"Med Mycol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"713687","DOI":"10.1155\/2012\/713687","volume":"2012","author":"Vandeputte P.","year":"2012","unstructured":"Vandeputte P.; Ferrari S.; Coste A.T.; 2012,2012,713687"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/jac\/dks481","volume":"68","author":"Jiang C.","year":"2013","unstructured":"Jiang C.; Dong D.; Yu B.; Cai G.; Wang X.; Ji Y.; Peng Y.; Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother 2013,68(4),778-785","journal-title":"J Antimicrob Chemother"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.myc.2016.11.001","volume":"58","author":"Chew K.L.","year":"2017","unstructured":"Chew K.L.; Cheng J.W.S.; Jureen R.; Lin R.T.P.; Teo J.W.P.; ERG11 mutations are associated with high-level azole resistance in clinical Candida tropicalis isolates, a Singapore study. Mycoscience 2017,58(2),111-115","journal-title":"Mycoscience"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"e0210397","DOI":"10.1371\/journal.pone.0210397","volume":"14","author":"Spettel K.","year":"2019","unstructured":"Spettel K.; Barousch W.; Makristathis A.; Zeller I.; Nehr M.; Selitsch B.; Lackner M.; Rath P.M.; Steinmann J.; Willinger B.; Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing. PLoS One 2019,14(1),e0210397","journal-title":"PLoS One"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12831","volume":"1354","author":"Perlin D.S.","year":"2015","unstructured":"Perlin D.S.; Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci 2015,1354(1),1-11","journal-title":"Ann N Y Acad Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1128\/AAC.00027-12","volume":"56","author":"Shields R.K.","year":"2012","unstructured":"Shields R.K.; Nguyen M.H.; Press E.G.; Kwa A.L.; Cheng S.; Du C.; Clancy C.J.; The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012,56(9),4862-4869","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1128\/AAC.01144-13","volume":"57","author":"Lewis J.S.","year":"2013","unstructured":"Lewis J.S.; Wiederhold N.P.; Wickes B.L.; Patterson T.F.; Jorgensen J.H.; Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother 2013,57(9),4559-4561","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1128\/AAC.00067-07","volume":"51","author":"Kahn J.N.","year":"2007","unstructured":"Kahn J.N.; Garcia-Effron G.; Hsu M-J.; Park S.; Marr K.A.; Perlin D.S.; Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007,51(5),1876-1878","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","volume":"49","author":"Park S.","year":"2005","unstructured":"Park S.; Kelly R.; Kahn J.N.; Robles J.; Hsu M-J.; Register E.; Li W.; Vyas V.; Fan H.; Abruzzo G.; Flattery A.; Gill C.; Chrebet G.; Parent S.A.; Kurtz M.; Teppler H.; Douglas C.M.; Perlin D.S.; Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005,49(8),3264-3273","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1128\/AAC.01653-05","volume":"50","author":"Balashov S.V.","year":"2006","unstructured":"Balashov S.V.; Park S.; Perlin D.S.; Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006,50(6),2058-2063","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1128\/AAC.01162-08","volume":"53","author":"Garcia-Effron G.","year":"2009","unstructured":"Garcia-Effron G.; Park S.; Perlin D.S.; Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: Implications for interpretive breakpoints. Antimicrob Agents Chemother 2009,53(1),112-122","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450122666210719124143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194896\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450122666210719124143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T07:18:55Z","timestamp":1699255135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194896\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450122666210719124143","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}